منابع مشابه
High-altitude pulmonary hypertension.
High-altitude pulmonary hypertension (HAPH) is a specific disease affecting populations that live at high elevations. The prevalence of HAPH among those residing at high altitudes needs to be further defined. Whereas reduction in nitric oxide production may be one mechanism for the development of HAPH, the roles of endothelin-1 and prostaglandin I₂ pathways in the pathogenesis of HAPH deserve f...
متن کاملPULMONARY HYPERTENSION Phosphodiesterase type 5 and high altitude pulmonary hypertension
Background: This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). Methods: 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملHigh-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude.
BACKGROUND Pulmonary hypertension has not been described as a predisposing risk factor for high-altitude pulmonary edema (HAPE) in children. Previous studies have shown an association of HAPE with abnormally increased pulmonary vasoreactivity to hypoxia but generally normal pulmonary artery pressure (PAP) after recovery. OBJECTIVE To describe HAPE of relatively rapid onset and its management ...
متن کاملHigh altitude-induced pulmonary hypertension in normal cattle.
• Elevation of the pulmonary arterial pressure is known to occur during hypoxia in a number of mammalian species. The mechanisms involved in the production of this hypertension are, however, not clearly understood. Most previous investigations have been concerned with the effect of short periods of severe hypoxia upon the pulmonary circulation. The effects of mild, prolonged hypoxia are less we...
متن کاملPhosphodiesterase type 5 and high altitude pulmonary hypertension.
BACKGROUND This study explored phosphodiesterase type 5 (PDE5) inhibition as a strategy for treating high altitude pulmonary arterial hypertension (HAPH). METHODS 689 subjects (313 men) of mean (SD) age 44 (0.6) years living above 2500 m were screened for HAPH by medical examination and electrocardiography, and 188 (27%) met the criteria for right ventricular hypertrophy. 44 underwent cardiac...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Respiratory Review
سال: 2009
ISSN: 0905-9180,1600-0617
DOI: 10.1183/09059180.00011104